KMT2A and leukemia: Based on the result of a phase Ib clinical trial, palbociclib has a positive effect in refractory/relapsed MLL (KMT2A)-rearranged leukemia patients with no incidence of limiting toxicities (NCT02310243) (Fröhling et al., 2016).